Identification of a Human Homologue of the Murine Tumor Rejection Antigen GP96

Pramod K. Srivastava and Lloyd J. Old

ABSTRACT

A family of cell surface glycoproteins with a molecular weight of 96,000 (gp96) has recently been implicated in the individually distinct immunogenicity of chemically induced sarcomas of inbred mice. Rabbit antisera to murine gp96 detects an antigenically related M, 96,000 cell surface glycoprotein on two cultured human melanoma cell lines, SK-MEL-13 and SK-MEL-177. Molecular probes for 5' and 3' ends of the murine gp96 gene detect a 3.5-kilobase transcript in RNA preparations from melanoma cells, similar to the murine gp96 transcript. While 5' probes do not hybridize to Southern blots of genomic human DNA, the 3' probes identify several distinct bands under stringent hybridization and washing conditions. This suggests that the 3' end of the gp96 gene is more conserved than its 5' end. No gross alterations in gp96 gene organization were detected in melanoma cells. B-lymphoblastoid cell lines derived from four different individuals also showed no restriction fragment polymorphism in the gp96 gene.

INTRODUCTION

Identification of tumor cell surface antigens recognized by autologous or syngeneic host remains the central issue of tumor immunology. In the study of human cancer, evidence for humoral (1) and cellular (2) immune recognition with specificity for human cancer cells continues to accumulate and a number of the antigens detected serologically have been characterized as gangliosides (3-5) and glycoproteins (5-8). In the case of experimental tumors, the clearest evidence for tumor-specific immunity comes from the demonstration of tumor rejection antigens that elicit transplantation immunity in syngeneic animals (9, 10). Recent studies have implicated M, 96,000 glycoproteins as the tumor rejection antigens of antigenically distinct chemically induced sarcomas of inbred mice (11). The present study describes the identification of a human cell surface antigen which shows homology with the murine tumor rejection antigen gp96, in terms of its serologically detected determinants and its molecular features.

MATERIALS AND METHODS

Cell Lines. Human melanoma cell lines SK-MEL-13 and -177 have been described (5).

Erythrocyte Rosetting. Detection of binding of antibodies to melanoma cell lines was carried out as described (5).

Preparation of Protein Extracts. Cells were scraped from the surface and washed three times with phosphate buffered saline. A cell pellet of 0.2 ml was suspended in 1 ml phosphate buffered saline containing 0.1 mM phenylmethyl sulfonylfluoride and the suspension was sonicated three times for 10 s each time while on ice. The cell lysate was centrifuged at 1000 x g for 10 min to remove whole cells and nuclei.

RESULTS AND DISCUSSION

Detection of a Murine gp96-Related Antigen on Human Melanoma. Generation of a rabbit antiserum to purified murine gp96 has been described in “Materials and Methods.” In erythrocyte rosetting assays for detection of cell surface antigens, this serum reacted (titer, 1:128) with two human melanoma cell lines SK-MEL-13 and -177; no reactivity was seen with non-immune rabbit serum. A surface-iodinated extract of SK-MEL-13 was immunoprecipitated with this serum and the precipitate was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. A single band of M, 96,000 was observed (Fig. 1). Protein extracts from the two cell lines were also analyzed by Western blotting. Partially purified murine gp96 prepared from the BALB/c sarcoma Meth A was also applied to the gels for comparison. The Western blots were probed with rabbit anti-gp96 antiserum and the nonimmune rabbit serum. The results show (Fig. 1) that rabbit anti-gp96 antiserum detects a molecule with 96,000 molecular weight in both melanoma cell lines. The murine and human melanoma gp96 molecules appear indistinguishable in size.

Northern Blot Analysis. Total RNA preparations from the two melanoma cell lines were probed with the murine gp96 probe pMA2 which defines the 5' end of the gp96 gene (14) and pV3, which defines the 3' end of the gene (3). In both melanomas, a 3.5-kilobase transcript, identical to the murine gp96 transcript, was detected with pMA2 and pV3 (Fig. 2).

Southern Blot Analysis. High molecular weight DNA from the cell line SK-MEL-13 was digested with restriction endonucleases BamHI, EcoRI, or PstI. Southern blots of these samples were probed with the 5' probe pMA2: under high and low stringency conditions, no reproducibly hybridizing bands were observed. However, when the same blots were probed with pV3, a cDNA fragment which defines the relatively 3' end of the murine gp96 gene, several bands were found to hybridize even under conditions of high stringency (Fig. 3). This observation suggests that the 5' region of the gp96 gene is less

Received 9/19/88; revised 12/5/88; accepted 12/14/88.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 This work was supported by a program project Grant CA-08748 of the National Cancer Institute, a grant from the Samuel Freeman Trust, and an American Cancer Society in-house award (114J) to P. K. S.

2 Recipient of a First Independent Research Support and Transition Award of the National Cancer Institute (CA-44786). To whom requests for reprints should be addressed at Box 1215, Department of Pharmacology, Mount Sinai School of Medicine, City University of New York, New York, NY 10029.

HUMAN HOMOLOGUE OF MURINE TUMOR ANTIGEN gp96

MW $x 10^{-3}$

1 2 3 4 5

200 92 68 43

Fig. 1. Immunochemical identification of human gp96. Lane 1, sodium dodecyl sulfate-polyacrylamide gel electrophoresis analysis of immunoprecipitate of $^{125}$I-surface-labeled SK-MEL-13 cells with rabbit anti-murine gp96 antiserum. Lanes 2 and 3, Western blots of extracts of BALB/c tumor Meth A (Lane 2) and SK-MEL-13 cells (Lanes 3) probed with rabbit anti-murine gp96. Lanes 4 and 5, Western blots of the same extracts probed with nonimmune rabbit serum.

Fig. 2. Northern blot hybridization of $^{32}$P-labeled pMA2 with poly(A)$^+$ RNA from BALB/c sarcoma Meth A (Lane 1) and total RNA from SK-MEL-13 (Lane 2) and SK-MEL-177 (Lane 3).

28S 18S

Fig. 3. Southern blot hybridization of $^{32}$P-labeled pMA2 with genomic DNA from SK-MEL-13 (left) and B-lymphoblastoid cell line NANN (right) derived from peripheral blood lymphocytes of a healthy individual. Southern blots of genomic DNA from SK-MEL-177 and Boleth, KT12, and Poco cell lines showed an identical pattern. DNA (15 ng/lane) was digested with BamHI (Lane 1), EcoRI (Lane 2) and Pstl (Lane 3).

lines and melanoma cells SK-MEL-13 and -177 (Fig. 3). Thus, there is no evidence for tumor-related rearrangement nor for individual-related structural variation in the gp96 gene.

Gp96 is also present in several other animal species$^4$ and may perform an essential function conserved across species. In this regard, the observed homology between murine gp96, the yeast heatshock protein hsp90, hamster glucose-regulated protein grp94, and the endoplasmic reticular protein ERp99 (15, 16) may be of significance.

Tumor transplantation studies in mice demonstrate that gp96 preparations elicit immunity specific to the tumor from which they are derived. This indicates that gp96 molecules have the potential for variability and hence, immunogenicity in the host of origin. Analysis of gp96 polymorphism in normal and malignant cells and its potential use as an immunogen in human cancer immunotherapy need to be explored.

ACKNOWLEDGMENTS

We thank Dr. Vivien R. Sutton for the gift of genomic DNA from B-lymphoblastoid cell lines derived from peripheral blood lymphocytes from normal donors.

REFERENCES


$^4$ Unpublished observations.


Identification of a Human Homologue of the Murine Tumor Rejection Antigen GP96

Pramod K. Srivastava and Lloyd J. Old


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/49/6/1341

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/49/6/1341.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.